|
Mechanismthymidine kinase modulators |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
比较肝移植手术联合重组腺病毒-胸苷激酶基因制剂和单纯肝移植术治疗进展期肝癌的临床生存期疗效和安全性
[Translation] Comparison of clinical survival efficacy and safety between liver transplantation combined with recombinant adenovirus-thymidine kinase gene preparation and liver transplantation alone in the treatment of advanced hepatocellular carcinoma
主要目的:比较进展期原发性肝细胞癌患者接受肝移植手术联合应用ADV-TK制剂治疗与单纯肝移植术的临床生存期疗效。
次要目的:观察进展期原发性肝细胞癌患者肝移植手术联合应用ADV-TK制剂治疗的安全性。
[Translation] Primary objective: To compare the clinical survival efficacy of liver transplantation combined with ADV-TK preparations and liver transplantation alone in patients with advanced primary hepatocellular carcinoma.
Secondary objective: To observe the safety of liver transplantation combined with ADV-TK preparations in patients with advanced primary hepatocellular carcinoma.
Phase II study of Recombinant Adenovirus-Herpes Simplex Virus Thymidine Kinase (ADV-TK) combined with Ganciclovir in recurrent head and neck cancer of late-stage
Phase II study of Recombinant Adenovirus-Herpes Simplex Virus Thymidine Kinase (ADV-TK) combined with Ganciclovir in primary hepatocellular carcinoma
100 Clinical Results associated with Shenzhen Tiandakang Gene Engineering Co., Ltd.
0 Patents (Medical) associated with Shenzhen Tiandakang Gene Engineering Co., Ltd.
100 Deals associated with Shenzhen Tiandakang Gene Engineering Co., Ltd.
100 Translational Medicine associated with Shenzhen Tiandakang Gene Engineering Co., Ltd.